CLAIMS

1. An ophthalmic composition comprising 0.05 to 0.3 (w/v) of hyaluronic acid or a salt thereof, 0.0005 to 0.005% (w/v) of chlorhexidine, 0.03 to 1.5% (w/v) of propylene glycol, and 0.015% (w/v) or less of ethylenediaminetetraacetate, provided that the ophthalmic composition does not comprise any of a polymer bearing a phosphorylcholine-analogous group in a side chain, glycyrrhizic acids or hyaluronidase.

2. The ophthalmic composition according to claim 1, wherein the concentration of propylene glycol is 0.05 to 1.0% (w/v).

3. The ophthalmic composition according to claim 1, wherein the concentration of ethylenediaminetetraacetate is 0.01% (w/v) or less.

4. The ophthalmic composition according to any one of claims 1 to 3, wherein the value of pH is 5.5 to 8.

5. The ophthalmic composition according to any one of claims 1 to 4, which is an eye drop for medical purposes, an eye drop for soft contact lenses, or a wearing agent for soft contact lenses.

6. A method of suppressing a temporal change in the kinetic viscosity of an ophthalmic composition comprising 0.05 to 0.3%

(w/v) of hyaluronic acid or a salt thereof and 0.0005 to 0.005% (w/v) of chlorhexidine, provided that the ophthalmic composition excludes a polymer bearing a phosphorylcholine-analogous group in a side chain, glycyrrhizic acids and hyaluronidase,

the method comprising allowing 0.03 to 1.5% (w/v) of propylene glycol and 0.015% (w/v) or less of ethylenediaminetetraacetate to be comprised of the ophthalmic composition.

7. A method of maintaining the antiseptic or preservative effect of an ophthalmic composition comprising 0.05 to 0.3% (w/v) of hyaluronic acid or a salt thereof and 0.0005 to 0.005% (w/v) of chlorhexidine at a high level, provided that the ophthalmic composition excludes a polymer bearing a phosphorylcholine-analogous group in a side chain, glycyrrhizic acids and hyaluronidase,

the method comprising allowing 0.03 to 1.5% b(w/v) of propylene glycol and 0.015% (w/v) or less of ethylenediaminetetraacetate to be comprised of the ophthalmic composition.

8. A method of suppressing a temporal change in the kinetic viscosity of an ophthalmic composition comprising 0.05 to 0.3% (w/v) of hyaluronic acid or a salt thereof and 0.0005 to 0.005% (w/v) of chlorhexidine and maintaining the antiseptic or preservative effect of the ophthalmic composition at a high

level, provided that the ophthalmic composition excludes a polymer bearing a phosphorylcholine-analogous group in a side chain, glycyrrhizic acids and hyaluronidase,

the method comprising allowing 0.03 to 1.5% (w/v) of propylene glycol and 0.015% (w/v) or less of ethylenediaminetetraacetate to be comprised of the ophthalmic composition.

9. A suppressing agent for suppressing a temporal change in the kinetic viscosity of an ophthalmic composition comprising 0.05 to 0.3% (w/v) of hyaluronic acid or a salt thereof and 0.0005 to 0.005% (w/v) of chlorhexidine, provided that the ophthalmic composition excludes a polymer bearing a phosphorylcholine-analogous group in a side chain, glycyrrhizic acids and hyaluronidase,

the suppressing agent comprising 0.03 to 1.5% (w/v) of propylene glycol and 0.015% (w/v) or less of ethylenediaminetetraacetate.

10. An antiseptic or preservative agent for maintaining the antiseptic or preservative effect of an ophthalmic composition comprising 0.05 to 0.3% (w/v) of hyaluronic acid or a salt thereof and 0.0005 to 0.005% (w/v) of chlorhexidine at a high level, provided that the ophthalmic composition excludes a polymer bearing a phosphorylcholine-analogous group in a side chain, glycyrrhizic acids and hyaluronidase,

the antiseptic or preservative agent comprising 0.03 to

1.5% (w/v)_ of propylene glycol and 0.015% (w/v) or less of ethylenediaminetetraacetate.